Novanta to Spend $1.45 Billion on Riverpoint Medical, Closing Q3 2026
NOVT•Novanta agreed to acquire Riverpoint Medical for $1.45 billion, including a $1.2 billion upfront payment and a $250 million milestone fee, to boost its minimally invasive surgical consumables portfolio. The deal, expected to close in Q3 2026, will be funded by $300 million equity, cash reserves and credit facility.
1. Acquisition Details
Novanta has agreed to acquire Riverpoint Medical for $1.45 billion, comprising a $1.2 billion upfront payment and a $250 million milestone. The transaction is slated to close in Q3 2026 and will integrate Riverpoint under Novanta’s medical solutions segment.
2. Financing Plan
The acquisition funding will come from $300 million raised through a recent private placement of common shares, existing cash on hand and the company’s credit facility, preserving financial flexibility for ongoing operations.
3. Strategic Rationale
The deal expands Novanta’s portfolio into minimally invasive surgical consumables, targeting more durable, recurring revenue streams, and is projected to double recurring medical consumables revenue to $300 million while boosting medical end-market concentration to 60% of total revenue.
4. Financial Backdrop and Outlook
Novanta reported nearly $1 billion in 2025 revenue, with automation technologies revenue of $501 million (up 2.1%) and medical solutions revenue of $480 million (up 4.6%). Integrating Riverpoint’s higher-growth profile, with a 12%–15% long-term revenue outlook, is expected to accelerate overall growth and cash flow.
